ArticleArthritis care & research2026
Role of Prednisone and 25-Hydroxyvitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reply.Arthritis care & research · 2026Article
- Clinical studies on glucocorticoid should document adherence to risk prevention strategies: comment on the article by Madanchi et al.Arthritis care & research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveWe evaluated the role of 25-hydroxyvitamin D (25[OH]D), prednisone, and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE).
methodsWe calculated the association between 25(OH)D levels and other potential risk factors and BMD measures (spine T scores) and osteoporosis (defined as a T score ≤ -2.5) in a lupus cohort of 1,003 patients. Generalized estimating equations were used to assess the statistical significance of observed differences, accounting for patients with multiple BMD measures.
resultsUnivariate analysis showed that older age, lower body mass index (BMI), mean past SLE activity (Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index > 2), mean daily prednisone dose at any level, and a history of low C3 or C4 were associated with osteoporosis. Older age, lower BMI, mean 25(OH)D levels, mean daily prednisone dose (again at any dose), and prior low C3 were associated with lower spine T scores. In the multivariate analysis for osteoporosis, older age, lower BMI, low mean 25(OH)D levels, and prednisone dose >5 mg/day remained predictors. Discontinuation of prednisone within one year before the next BMD measurement led to higher mean spine T scores.
conclusionPrednisone dose, even at 5 mg/day, and low mean 25(OH)D levels were found to be modifiable predictors of osteoporosis. Mean (reflecting supplementation), rather than initial, 25(OH)D levels were significantly associated with BMD. Some of the bone loss from prior prednisone use appears to be reversible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.